Breakthrough Discovery reverses Heart Disease

In 2016 a team of scientists from Germany's Bonn University discovered a new compound that reduced plaque in mice by over 40% in as little as 4 weeks.
The new cyclodextrin compound (CAVADEXTRIN®) was also tested on human plaque and they discovered it affected the plaque in a similar way.

After years of research, our RemChol tubes deliver 6 grams of CAVADEXTRIN® that circulates around the vascular system sucking up cholesterol and other lipids and transporting it out via the urinary system.

Angina dramatically reduced in 30 days. No diets or exercise.

Read the science
Cholrem is a world leader in the treatment of Heart Disease.

CAVADEXTRIN® was administered to our first patient at our Melbourne clinic in April 2019 and within 4 weeks the plaque was reduced.

CAVADEXTRIN® circulates around the cardiovascular system removing built up cholesterol and plaque resulting in significant plaque reduction.

CAVADEXTRIN® is absorbed via intravenous application or as an enema only. If taken orally it is destroyed in the gut and has no effect.

Regular low doses of CAVADEXTRIN® can have a significant effect on plaque build up over time.

12 grams of CAVADEXTRIN® was administered for 26 days over a 48 day period.
STUNNING RESULTS Lipids halved, Liver improves, Plaque reduced.

Lipids
Cholesterol from 10.6 (409) down to 4.1 (159)
Triglycerides from 20.0 (1771) down to 4.6 (409)
LDL from 3.7 (143) down to 1.8 (69)

Liver
GGT from 102 down to 78
ALT from 65 down to 37
AST from 42 down to 25

Remchol for home use

RemChol delivers CAVADEXTRIN® via an enema.
Each tube contains 8 grams of CAVADEXTRIN® with over 2 grams absorbed into the blood stream with every treatment.

Remchol tubes can be administered as often as one tube a day.

Available now

CAVADEXTRIN® clears the vascular system and can extend lifespan.

In 2014 at the University of Texas Southwest Medical Center, a study was conducted on the effects of Cyclodextrin administered to mice. They studied the lifespan of mice treated systemically with either saline or Cyclodextrin at weekly intervals starting at 49 days of age until death. In each case, half of the males and females were given Cyclodextrin and the remaining mice received only saline.

During the study, the mice were graded on their neurological function. There were no gender related differences in the neurological scores. This score, which broadly measures neurological function, declines as the animal’s condition deteriorates.
It is clear that Cyclodextrin treated mice showed higher neurological scores than compared with the mice given saline only.

All the mice given saline only had died by 98 days whereas the majority of those receiving Cyclodextrin died in the week following. This shows an almost 10% improvement in lifespan.

The human trial of CAVADEXTRIN conducted by Cholrem has consistantly shown the scientific evidence proving the benefits of Cyclodextrin on mice also has similar benefits on humans. It would be fair to assume that based on the science, humans treated with CAVADEXTRIN would also experience a similar benefit of lifespan extention as the mice.